<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140932</url>
  </required_header>
  <id_info>
    <org_study_id>Kappelgaard, ERG</org_study_id>
    <nct_id>NCT01140932</nct_id>
  </id_info>
  <brief_title>The Electroretinogram in Healthy and Glucose Intolerant Young Men</brief_title>
  <official_title>Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate the electroretinogram (ERG) in young, healthy men in the
      normoglycaemic and hyperglycaemic state before and after intervention with corticosteroids
      treatment, high calorie diet and exercise restraint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will be fasting from midnight the day before the experiment. Standard procedures
      (including pupil dilation, dark adaptation, and local anaesthetics) are carried out to allow
      the ERG to be obtained. After electrophysiology, the subject will be clamped at a plasma
      glucose level of 10 mM (~180 mg/dL) and after a stabilisation period the ERG protocol is
      repeated.

      Each subject is examined twice on two different days. The first day the subjects are
      normoglycaemic in the morning (first examination) and hyperglycaemic (clamped to 10 mM)
      throughout the second examination. The second day subjects are also normoglycaemic and
      hyperglycaemic but shows up after 7-12 days of daily intake of prednisolone, high calorie
      diet, and exercise restraint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ERG</measure>
    <time_frame>12 days</time_frame>
    <description>Characteristics of the scotopic ERG at normo-/hyperglycaemia before vs. after prednisolone treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Vessel Caliber</measure>
    <time_frame>12 days</time_frame>
    <description>Measurement of retinal vessel caliber from fundus photographs before and after treatment with glucocorticoids.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Electroretinography</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical and behavioural intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>12 days of corticosteroids treatment (prednisolone 37,5 mg/day)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Prednisolon DAK, Nycomed, Zurich, Switzerland</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle change</intervention_name>
    <description>High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Behavioral regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians without type 2 diabetes mellitus

          -  Normal OGTT (75 g glucose dissolved in 250 mL water) according to WHO's criteria

          -  BMI 20-30

          -  Haemoglobin &gt; 8,0 mM

        Exclusion Criteria:

          -  Nephropathy (s-creatinin &gt; 130 ÂµM or albuminuria)

          -  Relatives (parents or sibling with T2DM)

          -  Medical treatment which cannot be paused for 12 hours
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Larsen, MD, DMsc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital at Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Larsen, MD, DMsc</name_title>
    <organization>Glostrup University Hospital,Copenhagen</organization>
  </responsible_party>
  <keyword>Retina</keyword>
  <keyword>Electroretinography</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Glucose Intolerance</keyword>
  <keyword>Physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

